Burford Capital (BUR) : Why I Never Touch This Stock
A great analysis can end with a hard pass. Here's exactly why Burford Capital, despite its genuine strengths fails my personal investing framework.
0. THE STORY
The Genesis. Two lawyers looked at the $400+ billion spent on litigation globally every year and spotted a broken market: companies with legitimate legal claims were either settling too cheap or walking away entirely because lawsuits are expensive and outcomes uncertain. Burford Capital, founded in 2009, essentially invented institutional litigation finance you have a strong legal claim but can’t afford the fight? We fund it, take the risk, and share the proceeds when you win.
The Current Drama. Burford just reported a weak FY2025, with revenue down 17% from record 2024 levels despite the underlying portfolio growing 20% and new commitments jumping 39%. The earnings drop was almost entirely accounting noise fair-value adjustments on ongoing cases not actual losses. Meanwhile, a $16 billion judgment against the Argentine government is sitting at the US Court of Appeals, where the panel has publicly signaled skepticism. The stock is down 45% from its 52-week high and trading below book value.
Why This Matters. The bull case on Burford is coherent, the moat is real, and the valuation looks cheap on paper. This analysis exists to work through all of it honestly and to explain why, at the end of a genuinely compelling story, the framework still says pass.
1. THE MACHINE
The Simple Explanation. Think of Burford as a venture capital firm for lawsuits. A corporation has a legitimate $500M breach-of-contract claim but paying lawyers for years is expensive and distracting. Burford writes the check covering all legal costs in exchange for a cut of the eventual settlement or judgment. They only win if the case wins. No interest income, no monthly payments. Pure risk-for-reward investing in the outcomes of commercial disputes. The twist: these returns are almost completely uncorrelated to the stock market. When the economy tanks, companies sue each other more, not less.
The Moat. Burford’s moat is real and has three layers. First, proprietary data: fifteen years of private case outcomes thousands of settlements that never become public is a genuine informational edge no competitor can replicate. Second, capital access: as the only NYSE-listed litigation finance firm, Burford can tap public debt markets at a scale and cost that private competitors like Longford or Therium simply cannot match their July 2025 $500M notes issuance at 7.5% is an option no private rival even has on the table. Third, relationships: they work with 90 of the world’s 100 largest law firms, a distribution network built over a decade that no new entrant can shortcut. These are genuine structural advantages. They’re just not enough, for reasons we’ll get to.
The ROIC Story. On concluded cases, Burford has historically generated 83–87% ROIC meaning they roughly double invested capital every two to three years on winning cases. Their annualized IRR across the portfolio has run at 27–30%. That is genuinely exceptional and puts them in the top tier of any asset class globally. The business is a compounder as long as it can keep redeploying capital at similar rates. The current portfolio stands at $3.9 billion in principal finance assets, growing 20% in FY2025. Even in a so-called “weak” year, the machine kept working. The problem isn’t the ROIC. It’s everything wrapped around it.
The Risks. Four risks, ranked by severity. First, a single US Appeals Court decision on the YPF case can impair 30–40% of market cap overnight a binary event entirely outside management’s control. Second, regulatory pressure from well-funded opponents is building simultaneously in the US, EU, and UK, targeting the very existence of third-party litigation finance. Third, interest coverage of 1.9x leaves almost no cushion in a business with inherently volatile annual cash flows. Fourth, fair-value accounting on an opaque portfolio creates persistent credibility questions a transparency problem that generates a structural valuation discount that may never fully close. Each of these risks gets its own filter below. None of them is theoretical.
2. THE NUMBERS
Current Valuation
Price (NYSE): ~$8.50
Market Cap: ~$1.9B
Enterprise Value: ~$3.3B (Market Cap + $2B debt − $621M cash)
Book Value per Share: ~$10.50 → stock trades at 0.80x book
Profitability Snapshot
Revenue (TTM): $466M down 17% from FY2024, despite portfolio growing 20%. This gap is the whole story.
Net Income (TTM): ~$87M GAAP; treat as directional only given fair-value swings
Operating Margin: ~57% structurally high; litigation finance has near-zero cost of goods sold
Note on FCF: free cash flow is nearly meaningless here the company recognizes revenue only when multi-year cases conclude, making cash generation episodic by design
Valuation Metrics
P/E Ratio: ~22x almost useless; use price-to-book instead
Historical P/Book Range (5Y): Low 0.7x (COVID panic) High 3.2x (2021 peak) — Avg: ~1.4x
Earnings Yield: ~4.7% on GAAP earnings
vs 10Y US Treasury: ~4.3% → the stock offers essentially no premium over risk-free on reported earnings
vs S&P 500 Earnings Yield: ~4.0% → marginal premium, not enough for this risk profile
Interpretation: on reported earnings yield, Burford barely clears the risk-free rate. The bull case requires trusting that normalized earnings are 2–3x the reported figure which may be right, but demands confidence in fair-value marks that have been publicly questioned
Shareholder Returns
Dividend Yield: ~0.7% a rounding error
Buyback Yield: ~0% no material repurchase program
Total Shareholder Yield: ~0.7% this is purely a capital gains story; there is no income floor whatsoever
Quality Indicators
Debt/Equity: 55% up from 36% five years ago; the trend is the wrong direction
Interest Coverage: 1.9x dangerously thin for a business with volatile annual cash flows; one slow year for case conclusions could push this below 1.3x
3. THE NAPKIN MATH
A. Growth Driver
Portfolio growth rate: ~15–20% annually (management targeting double by 2030, currently on pace)
Revenue growth on normalized basis: ~12–15% (conservative — assumes some case timing drag persists)
Margin: already near-peak at 57%; minimal expansion room
Share count: stable, no buyback program
Total EPS Growth Estimate: ~12–15% annually (normalized)
B. Shareholder Yield
Dividend Yield: 0.7%
Buyback Yield: 0%
Total: ~0.7%
C. Valuation Impact
Current P/Book: 0.80x
Historical Average P/Book (5Y): ~1.4x
Bull assumption: reversion to 1.4x over 5 years: (1.4/0.8)^(1/5) − 1 = +12% per year boost
Base assumption: partial reversion to 1.1x: +6% per year boost
Bear assumption: stays at 0.80x (regulatory overhang + YPF uncertainty persist): 0% contribution
D. The Final Equation
The base case looks genuinely attractive versus the S&P 500’s historical ~10%. The bull case is outstanding. But the stress scenario Second Circuit reverses YPF, regulatory noise increases, one slow case year produces near-zero returns for five years. That wide distribution, anchored by a binary legal event you cannot model, is the core problem. You’re not buying a compounder at a discount. You’re buying a compounder with a lottery ticket stapled to it. The question is whether you wanted the lottery ticket.